Paclitaxel oral - Solural Pharma
Alternative Names: SOL-606Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator Solural Pharma
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in Denmark (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in Denmark (PO)
- 08 Dec 2015 Preclinical trials in Cancer in Denmark (PO) prior to December 2015 (Solural pipeline, December 2015)